HOME >> MEDICINE >> NEWS
Oral formulation of antipsychotic offers 'user-friendly' alternative to injections for patients with acute psychosis

[11 September 2000, Munich] -- Although many physicians rely on intramuscular injections of antipsychotic drugs to treat patients who need emergency treatment for psychotic agitation, new research has found that the oral-solution form of Risperdal™ (risperidone) is just as effective and may be a more acceptable alternative for both caregivers and patients(1).

The study, which was presented today at a major international neuropsychopharmacology congress in Munich, found that Risperdal works as quickly and is as effective in reducing symptoms of psychotic agitation as an intramuscular (IM) injection of haloperidol, an older, conventional antipsychotic. Both medications were administered in combination with the antianxiety drug lorazepam.

"When there are two drugs that are equally efficacious, a physician's next consideration when selecting an antipsychotic drug in emergency situations should be patient choice and compliance," said Dr Glenn Currier, lead investigator and assistant professor of the departments of psychiatry and emergency medicine at the University of Rochester. "When patients experiencing psychotic agitation -- usually due to schizophrenia -- end up in the emergency room, they often are confused, scared and paranoid. Injections are painful, and can be perceived as hostile and 'coercive.' This can be a significant barrier to the physician's ability to deliver good care, and to the patient's ability to accept it."

In contrast, an oral solution (liquid) is more easily administered in emergency situations than pills, and is non-invasive. Patients also can continue on the same medication when they leave the hospital, which encourages long-term compliance. Dr. Currier adds that an oral-solution formulation offers benefits to caregivers as well. Injections expose staff members at hospitals and other facilities to an increased risk of needlepricks and a resultant exposure to diseases such as AIDS and hepatitis -- especially w
'"/>

Contact: John Gisborne
john.gisborne@ketchumcomms.co.uk
44-207-465-8753
Ketchum
10-Sep-2000


Page: 1 2 3

Related medicine news :

1. Newer formulation of heparin improves outcomes for suspected heart attack patients
2. Newer vitamin D formulation appears to help dialysis patients live longer
3. Bristol-Meyers Squibb submits NDA for new formulation of once daily videx(R)(didanosine)
4. Researchers warn antipsychotic drug
5. New antipsychotic drugs combined with nicotine patch help schizophrenics quit smoking
6. New study shows prescribing of newer antipsychotic medication risperdal may save millions in schizophrenia care
7. UCSF study offers insight into human circadian rhythms
8. Research offers hope of new treatments for liver damage
9. Portable system offers dialysis patients liberating changes
10. New laparoscopic hysterectomy offers quicker recovery time than traditional surgery
11. UIC offers new weight loss surgery for obese teens

Post Your Comments:
(Date:1/22/2015)... January 23, 2015 LunaDress, with its top ... fashion industry. Now, the business is showing its latest designs ... dresses. , According to the company’s CEO, all the fresh ... offered with big discounts, up to 80% off. All the ...
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: